Britain and America have concluded a key trade agreement that will preserve no levies on UK medicine exports being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to increase expenditure on drugs through the National Health Service (NHS). This pledge secures that import taxes on these vital exports will stay at nothing for a timeframe of the next three years.
This development is in response to recent threats to hike duties on branded drug products, with figures floated as high as double the cost.
"This deal with the UK strengthens the global environment for innovative medicines and brings long-overdue fairness to U.S.–U.K. drug exports," a statement noted.
Trade Importance
Drugs constitute one of the UK's largest export categories to the America, which is easily the biggest destination for major companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period leading up to last September, the UK sold pharmaceutical products valued at £11.1bn to the US. This figure represented a significant portion of total UK exports in that span.
"This agreement safeguards work, increases funding and paves the way for the UK to become a international leader for medical research," a government official commented.
Specific NHS Changes
The deal involves several specific commitments from the UK:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to control costs will be restricted at fifteen percent. In the past, rebates exceeded 20%.
Recent Tensions
The deal follows a long-running tension between the sector and the UK government over medicine costs and NHS adoption.
The disagreement were intensified by claims that American patients were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been pledged toward US facilities.
One official acknowledged that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had shrunk as a share of its resources over the last ten years.
